

Efficient synthesis and characterization of novel isoxazole derivatives including dihydropyrazole and methanoisindole moieties

Meliha Burcu Gürdere ¹ Fatih Ertürk ² Yakup Budak ^{1*} and Mustafa Ceylan ¹

¹Department of Chemistry, Faculty of Arts and Sciences, Tokat Gaziosmanpaşa University, 60250 Tokat, Türkiye

²Vocational School, Occupational Health and Safety Programme, Istanbul Arel University, Istanbul, Türkiye

(Received May 19, 2020; Revised June 11, 2020; Accepted June 14, 2020)

Abstract: Isoxazole and pyrazole derivatives have a wide range of biological activity and they are of great interest to medicinal chemist. In this study, the synthesis and characterization of a series of novel hybrid molecules containing pyrazole and isoxazole rings ((3a*S*,4*S*,4a*R*,7a*S*,8*S*,8a*S*)-6-(4-(1-acetyl-5-(4-(aryl/heteroaryl))-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4a,8,8a-tetrahydro-3a*H*-4,8-methanoisoxazolo [4,5-*f*] isindole-5,7(6*H*,7a*H*)-dione derivatives) were reported.

Keywords: Isoxazole; synthesis; characterization; NMR. © 2020 ACG Publications. All rights reserved.

1. Introduction

Five membered heterocycles such as thiazole,¹ dihydropyrazol² and tetrahydroisoxazole derivatives³ are very important compounds due to their biological activities. These compounds can be easily synthesized by addition hydrazine and nitrile oxides to α,β -unsaturated compounds such as chalcones.^{4,5} Tetrahydroisoxazole derivatives are an important class of heterocyclic pharmaceuticals and bioactive natural products, which have been widely applied in medicinal chemistry, material science, natural products, and some other fields.⁶ Great efforts have been made on the synthesis of isoxazole and their derivatives⁷ due to their biological activities, including exhibit analgesic,⁸ antinociceptive,⁹ anticancer,¹⁰ antitubercular,¹¹ potent and selective antagonism of the NMDA receptor¹² and anti-HIV activity¹³ may allow differing helical strands. Also, isoxazoline and tetrahydroisoxazoles are versatile intermediates for the synthesis of a variety of bioactive compounds. For the synthesis of five membered heterocycles, cycloaddition reactions is one of the most effective methods.^{14,15} The 1,3-dipolar cycloaddition of nitrile oxides to alkenes is a widely used for the synthesis of tetrahydroisoxazoline derivatives³.

* Corresponding author: E-mail: yakup.budak@gop.edu.tr

In addition, dihydropyrazole is an important heterocyclic compound that is of intense interest to medical chemists because of its wide spectrum of biological activity. Easily synthesized dihydropyrazoles have important activities such as antimicrobial,¹⁶ anticancer,¹⁷ antioxidant,¹⁸ antiamebic,¹⁹ anti-inflammatory,²⁰ antidiabetic,²¹ diuretic²² and carbonic anhydrase inhibition.²³

In this study, as a continuation of our previous work, the synthesis and characterization of a series of novel hybrid molecules containing dihydropyrazole and tetrahydroisoxazole rings ((3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(4-(aryl/heteroaryl))-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione derivatives were reported.

2. Experimental

2.1. Chemical Materials and Apparatus

All chemicals and solvents were obtained from Merck (Germany) and Fluka (Germany). Melting points were measured on an Electrothermal 9100 apparatus. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance DPX-400 instrument. IR spectra (KBr disc) were recorded on a Jasco FT/IR-430 spectrometer. Elemental analyses were obtained from a LECO CHNS 932 Elemental Analyzer.

2.2. General procedure for the synthesis of (3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(4-(aryl/heteroaryl))-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione derivatives

Compounds **1a-j** (1 equiv.) and acetaldehyde oxime (4 equiv.) were dissolved in CH₂Cl₂ and cooled in the ice bath. Then NaOCl (4 equiv.) was added to this solution as dropwise. The reaction mixture was stirred at room temperature for 6 hours. At the end of the reaction, the mixture was extracted with CH₂Cl₂. The organic phase was dried with Na₂SO₄, and the solvent was removed on the evaporator. The products were crystallized with CH₂Cl₂-Hexane.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1*H*-pyrazol-3-yl) phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3a**): Yield, 75%; m.p. 123-127 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.86 (d, *J* = 6.4 Hz, 2H), 7.35 (d, *J* = 1.6 Hz, 2H), 7.18-7.14 (m, 2H), 6.87-6.84 (m, 2H), 5.60-5.54 (dd, *J* = 11.8 Hz, 4.2 Hz, 1H), 4.65 (d, *J* = 8.0 Hz, 1H), 3.79 (s, 3H), 3.78-3.71 (m, 1H), 3.41-3.31 (m, 2H), 3.19 (s, 3H), 3.13-3.12 (d, *J* = 4.8 Hz, 1H), 2.41 (bs, 3H), 1.98 (bs, 3H), 1.88-1.85 (d, *J* = 11.2 Hz, 1H), 1.68-1.65 (d, *J* = 11.2 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 176.5 (2C), 168.9, 159.1, 159.0, 154.5, 152.5, 134.6, 132.6, 127.3 (2C), 127.1 (2C), 126.9 (2C), 81.5, 59.6, 56.2, 52.3, 46.0, 45.8, 44.3, 42.1, 35.9, 29.6, 22.0, 11.7. IR (KBr, cm⁻¹): 3005, 2985, 2968, 1768, 1711, 1673, 1603, 1511, 1444, 1411, 1366, 1323, 1257, 1172, 1125, 1063, 1035, 1017. Elemental Analysis Anal. calcd for C₂₉H₂₈N₄O₅: C, 67.96; H, 5.51; N, 10.93; Found: C, 68.09; H, 5.48; N, 10.97.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(*p*-tolyl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3b**): Yield 65%; m.p. 133-138 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.79 (d, *J* = 8.4 Hz, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 7.11 (bs, 4H), 5.57-5.53 (dd, *J* = 11.6 Hz, 4.4 Hz, 1H), 3.73-3.66 (dd, *J* = 17.6 Hz, 11.6 Hz, 1H), 3.51 (bs, 1H), 3.45-3.44 (m, 3H), 3.14-3.08 (dd, *J* = 17.8 Hz, 4.6 Hz, 1H), 2.41 (bs, 3H), 2.30 (bs, 2H), 1.79 (d, *J* = 8.8 Hz, 1H), 1.62 (d, *J* = 8.8 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 176.6 (2C), 169.0, 154.5, 152.9, 138.8, 137.4, 134.6, 133.3 (2C), 131.5, 129.1, 127.1, 126.8 (2C), 125.5 (2C), 59.9, 52.3, 47.1, 45.8, 45.5, 42.2, 25.3, 22.0, 21.1, 11.7. IR (KBr, cm⁻¹): 2974, 2961, 1768, 1718, 1676, 15916, 1513, 1440, 1409, 1353, 1327, 1258, 1172, 1131, 1058, 1034, 1014. Elemental Analysis Anal. calcd for C₂₉H₂₈N₄O₄: C, 70.15; H, 5.68; N, 11.28; Found: C, 70.09; H, 5.62; N, 11.34.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(3-chlorophenyl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazol[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3c**): Yield 565; m.p. 132-135 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.82 (d, *J* = 7.6 Hz, 2H), 7.32 (d, *J* = 7.6 Hz, 2H), 7.28-7.17 (m, 3H), 7.10-7.08 (dd, *J* = 6.8 Hz, 1,2 Hz, 1H), 5.57-5.52 (dd, *J* = 12 Hz, 4.8 Hz, 1H), 4.61 (d, *J* = 7.6 Hz, 1H), 3.78-3.70 (dd, *J* = 17.6 Hz, 12 Hz, 1H), 3.36-3.28 (m, 2H), 3.19-3.08 (m, 3H), 3.09-2.96 (m, 1H), 2.42 (bs, 3H), 1.94 (bs, 3H), 1.79 (d, *J* = 11.2 Hz, 1H), 1.63 (d, *J* = 11.2 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 176.5 (2C), 169.0, 154.5, 152.7, 143.6(2C), 134.8, 134.6, 133.4, 131.2, 130.2, 128.0, 127.2 126.8, 125.7 (2C), 81.5, 59.6, 56.2, 46.5, 44.3, 42.1, 41.2, 35.9, 25.3, 21.9, 11.7. IR (KBr, cm⁻¹): 2987, 2978, 1772, 1714, 1670, 1596, 1511, 1433, 1410, 1357, 1321, 1255, 1166, 1121, 1060, 1031, 1012. Elemental Analysis Anal. calcd for C₂₈H₂₅ClN₄O₄: C, 65.05; H, 4.87; N, 10.84; Found: C, 65.01; H, 4.83; N, 10.79.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazol[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3d**): Yield 62%; m.p. 160-164 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.85 (d, *J* = 8.8 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.25 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.8 Hz, 2H), 5.60-5.54 (m, 1H), 4.65 (d, *J* = 8 Hz, 1H), 3.78-3.74 (dd, *J* = 9.6; 6.0 Hz, 1H), 3.42-3.32 (m, 1H), 3.20 (d, *J* = 6.4 Hz, 3H), 3.16-3.08 (m, 1H), 3.00 (d, *J* = 4.8 Hz, 1H), 2.42 (s, 3H), 1.97 (s, 3H), 1.85-1.82 (d, *J* = 11.2 Hz, 1H), 1.68-1.65 (d, *J* = 11.2 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 176.5 (2C), 168.9, 154.5, 152.2, 140.1, 134.6, 133.5, 131.7, 129.1 (2C), 129.1 (2C), 126.8 (2C), 126.7 (2C), 81.5, 59.6, 56.2, 46.5, 44.3, 42.1, 41.2, 35.9, 25.3, 21.9, 11.7. IR (KBr, cm⁻¹): 2997, 2988, 1769, 1717, 1670, 1596, 1518, 1438, 1405, 1359, 1326, 1257, 1174, 1123, 1065, 1039, 1018. Elemental Analysis Anal. calcd for C₂₈H₂₅ClN₄O₄: C, 65.05; H, 4.87; N, 10.84; Found: C, 65.12; H, 4.83; N, 10.78.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(2-bromophenyl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazol[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3e**): Yield 74%; m.p. 175-180 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.85 (d, *J* = 8.4 Hz, 2H), 7.61 (d, *J* = 7.6 Hz, 1H), 7.33-7.26 (m, 3H), 7.15 (t, *J* = 7.0 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 5.97-5.92 (dd, *J* = 11.2, 7.2 Hz, 1H), 4.65 (d, *J* = 8 Hz, 1H), 3.92-3.84 (dd, *J* = 12.0, 5.6 Hz, 1H), 3.41-3.31 (m, 2H), 3.19 (brs, 3H), 3.08-3.01 (m, 1H), 2.51 (s, 3H), 1.98 (s, 3H), 1.84 (d, *J* = 10.8 Hz, 1H), 1.67 (d, *J* = 10.4 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 174.8 (2C), 168.9, 154.5, 152.2, 139.8, 133.2, 132.7, 131.8, 129.1, 127.9, 127.3(2C), 126.6 (2C), 121.5, 81.5, 60.1, 56.2, 46.0, 41.5, 41.2, 35.9, 29.7, 21.9, 11.7. IR (KBr, cm⁻¹): 2998, 2958, 1772, 1714, 1671, 1592, 1519, 1438, 1405, 1367, 1322, 1251, 1162, 1124, 1066, 1037, 1014. Elemental Analysis Anal. calcd for C₂₈H₂₅BrN₄O₄: C, 59.90; H, 4.49; N, 9.98; Found: C, 59.86; H, 5.51; N, 10.02.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(3-bromophenyl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazol[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3f**): Yield 58%; m.p. 141-145 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.85 (d, *J* = 8.4 Hz, 2H), 7.41-7.38 (m, 1H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.26-7.14 (m, 3H), 5.59-5.55 (dd, *J* = 12.2 Hz, 4.6 Hz, 1H), 4.65 (d, *J* = 8 Hz, 1H), 3.80-3.71 (m, 1H), 3.41-3.31 (m, 1H), 3.21-3.19 (m, 3H), 3.17-3.13 (m, 1H), 3.01-3.00 (d, *J* = 4.8 Hz, 1H), 2.43 (s, 3H), 1.97 (s, 3H), 1.85-1.82 (d, *J* = 11.2 Hz, 1H), 1.68-1.65 (d, *J* = 11.2 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 175.4 (2C), 168.9, 154.5, 152.7, 143.8, 134.6 (2C), 130.9, 130.5 (2C), 128.6 (2C), 127.4, 127.2, 126.8, 123.0, 81.5, 59.9, 56.2, 46.5, 45.5, 42.1, 41.2, 35.9, 29.7, 21.9, 11.7. IR (KBr, cm⁻¹): 3010, 2975, 2962, 1775, 1716, 1673, 1582, 1514, 1438, 1405, 1358, 1326, 12538, 1163, 1123, 1063, 1035, 1014. Elemental Analysis Anal. calcd for C₂₈H₂₅BrN₄O₄: C, 59.90; H, 4.49; N, 9.98; Found: C, 59.94; H, 4.45; N, 9.94.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(4-bromophenyl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazol[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3g**): Yield 54%; m.p. 136-140 °C. ¹H-NMR (400 MHz, CDCl₃, ppm): δ = 7.83 (d, *J* = 8.8 Hz, 2H), 7.32 (d, *J* = 8.8 Hz, 2H), 7.23 (d, *J* = 8.8 Hz, 2H), 7.16 (d, *J* = 8.0 Hz, 2H), 5.55-5.49 (m, 1H), 4.62 (d, *J* = 8 Hz, 1H), 3.71-3.68 (m, 1H), 3.36-3.30 (m, 1H), 3.18 (d, *J* = 8.0 Hz, 3H), 3.09-3.05 (m, 1H), 2.97 (d, *J* = 4.8 Hz, 1H), 2.40 (s, 3H), 1.94 (s, 3H), 1.79 (d, *J* = 9.2 Hz, 1H), 1.61 (d, *J* = 8.0 Hz, 1H). ¹³C-NMR (100 MHz, CDCl₃): δ = 176.5 (2C), 168.9, 154.6, 152.6, 140.7, 134.6, 132.8, 131.6 (2C), 131.2

(2C), 129.0 (2C), 127.3 (2C), 121.5, 81.5, 52.3, 45.5, 44.3, 42.0, 41.2, 35.8, 25.3, 21.9, 21.4, 11.7. IR (KBr, cm^{-1}): 3014, 2989, 2968, 1762, 1724, 1680, 1584, 1512, 1434, 1408, 1353, 1322, 1253, 1168, 1122, 1060, 1031, 1012. Elemental Analysis Anal. calcd for $\text{C}_{28}\text{H}_{25}\text{BrN}_4\text{O}_4$: C, 59.90; H, 4.49; N, 9.98; Found: C, 59.87; H, 5.54; N, 10.05.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(furan-2-yl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3h**): Yield 60%; m.p. 205-208 °C. ^1H NMR (400 MHz, CDCl_3 ppm) δ : 7.89 (dd, $J = 6.8, 2.0$ Hz, 2H), 7.35 (dd, $J = 8.4, 1.6$ Hz, 2H), 7.32 (m, 1H), 6.36-6.33 (m, 2H), 5.73 (dd, $J = 11.8; 4.6$ Hz, 1H), 4.67 (d, $J = 8.4$ Hz, 1H), 3.63 (dd, $J = 17.6, 11.6$ Hz, 1H), 3.58 (d, $J = 11.6$ Hz, 1H), 3.48 (d, $J = 4.8$ Hz, 1H), 3.44-3.33 (m, 2H), 3.22 (d, $J = 6.8$ Hz, 2H), 3.02 (d, $J = 4.8$ Hz, 1H), 2.41 (s, 3H), 1.99 (s, 3H), 1.85 (d, $J = 11.2$ Hz, 1H), 1.68 (d, $J = 11.2$ Hz, 1H). ^{13}C -NMR (100 MHz, CDCl_3 ppm) $\delta = 175.5, 174.9, 169.1, 154.6, 152.8, 151.9, 142.1, 132.7, 131.9, 127.4, 126.7, 110.6, 107.8, 81.5, 56.3, 53.6, 46.6, 46.1, 44.4, 41.3, 38.1, 35.9, 22.0, 11.8$. IR (KBr, cm^{-1}): 3114, 2979, 2958, 1772, 1714, 1670, 1596, 1517, 1441, 1408, 1363, 1320, 1255, 1173, 1127, 1060, 1032, 1013. Elemental Analysis Anal. calcd for $\text{C}_{26}\text{H}_{24}\text{N}_4\text{O}_5$: C, 66.09; H, 5.12; N, 11.86; Found: C, 66.03; H, 5.08; N, 11.91.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(thiophen-2-yl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3i**): Yield 70%; m.p. 174-176 °C. ^1H NMR (400 MHz, CDCl_3 ppm) δ : 7.9 (brd, $J = 8.4$ Hz, 2H), 7.36 (brd, $J = 8.4$ Hz, 2H), 7.21 (dd, $J = 5.2, 1.2$ Hz, 1H), 7.05 (d, $J = 3.6$ Hz, 1H), 6.95 (dd, $J = 5.2, 3.6$ Hz, 1H), 5.96 (dd, $J = 11.4, 3.6$ Hz, 1H), 4.67 (d, $J = 8.4$ Hz, 1H), 3.75 (dd, $J = 17.6, 11.6$ Hz, 1H), 3.43-3.33 (m, 3H), 3.22 (d, $J = 7.2$ Hz, 2H), 3.02 (d, $J = 4.8$ Hz, 1H), 2.42 (s, 3H), 1.99 (s, 3H), 1.86 (d, $J = 11.2$ Hz, 1H), 1.69 (d, $J = 11.2$ Hz, 1H). ^{13}C -NMR (100 MHz, CDCl_3 ppm) $\delta = 175.5, 174.9, 169.0, 154.6, 152.6, 134.0$ (2C), 132.7, 131.9, 127.4, 126.9, 126.7, 124.9, 124.7, 81.6, 56.3, 55.5, 46.6, 46.1, 44.4, 41.9, 41.3, 35.9, 22.0, 11.8. IR (KBr, cm^{-1}): 3127, 2971, 2960, 1772, 1760, 1666, 1519, 1409, 1376, 1326, 1172. Elemental Analysis Anal. calcd for $\text{C}_{26}\text{H}_{24}\text{N}_4\text{O}_4\text{S}$: C, 63.92; H, 4.95; N, 11.47; S, 6.56; Found: C, 63.87; H, 5.50; N, 11.51; S, 6.84.

(3*aS*,4*S*,4*aR*,7*aS*,8*S*,8*aS*)-6-(4-(1-acetyl-5-(pyridin-4-yl)-4,5-dihydro-1*H*-pyrazol-3-yl)phenyl)-3-methyl-4,4*a*,8,8*a*-tetrahydro-3*aH*-4,8-methanoisoxazolo[4,5-*f*]isoindole-5,7(6*H*,7*aH*)-dione (**3j**): Yield 55%; m.p. 260-63°C. ^1H NMR (400 MHz, CDCl_3 ppm) δ : 8.60 (brs, 2H), 7.85 (d, $J = 8.4$ Hz, 2H), 7.35 (d, $J = 8.4$ Hz, 2H), 5.59 (dd, $J = 12.0, 4.8$, 1H), 3.80 (dd, $J = 17.8, 12.0$ Hz, 1H), 3.73 (dd, $J = 14.0, 6.8$ Hz, 1H), 3.42-3.32 (m, 3H), 3.20 (d, $J = 8.4$ Hz, 2H), 3.16 (d, $J = 4.8$ Hz, 1H), 3.11 (d, $J = 4.8$ Hz, 1H), 2.47 (s, 3H), 1.97 (s, 3H), 1.86 (d, $J = 11.2$ Hz, 1H), 1.67 (d, $J = 11.2$ Hz, 1H). ^{13}C -NMR (100 MHz, CDCl_3 ppm) $\delta = 176.6, 175.6, 169.2, 153.0, 152.8, 150.3, 150.0$ (2C), 140.9, 133.6, 130.8, 127.3, 127.0, 126.1 (2C), 81.4, 59.1, 52.2, 45.9, 45.8, 44.3, 41.7, 35.9, 21.7, 18.2, 11.6. IR (KBr, cm^{-1}): 3114, 2979, 2958, 1772, 1714, 1670, 1596, 1517, 1438, 1405, 1363, 1322, 1253, 1168, 1122, 1060, 1031, 1012. Elemental Analysis Anal. calcd for $\text{C}_{27}\text{H}_{25}\text{N}_5\text{O}_4$: C, 67.07; H, 5.21; N, 14.48; Found: C, 67.13; H, 5.17; N, 14.52.

3. Results and Discussions

The starting compounds **1a-j** were synthesized by our previously published procedure.^{24,25} Then the reaction of compounds **1a-j** with acetaldoxime (**2**) (4 equiv.) in the presence of NaOCl (4 equiv.) in CH_2Cl_2 at 0-5°C for 6 hours gave the isoxazole derivatives (**3a-j**) in moderate to good yields (54-75%) (Scheme 1, Table 1). The products **3a-j** were purified by crystallization in CH_2Cl_2 -Hexane. It was observed that electron donating groups in the phenyl ring increased the yield (Table 1, Entry 1) while the electron withdrawing groups decreased the yield (Table 1, Entry 10).





Figure 1. Numbering scheme for compound 2h

Table 1. Synthesized compounds 3a-j

Entry	Compound	Compound No	Yield (%)	M.p. (°C)
1		3a	75	124-127
2		3b	65	135-138
3		3c	56	132-135
4		3d	62	160-164
5		3e	74	177-180
6		3f	58	141-145
7		3g	54	136-140
8		3h	60	205-208
9		3i	70	174-176
10		3j	55	260-263



Scheme 1. Synthesis of **3a-j**

When acetaldoxime is added to the double bond, it is expected that the endo and exo products will be formed, but only endo addition was observed in this reaction. In the literature, in the 1,3-dipolar cycloaddition of nitrile oxides to bicyclo[2.2.1]heptene systems, it is reported the only endo product was formed.^{3, 26, 27}

The structures of compounds **3a-j** were explained by spectral data (IR, ¹H-NMR and ¹³C-NMR) and Elemental analysis. The **3h** was chosen as an example to explain the structures of the compounds. In the ¹H-NMR spectrum of compound **3h**, the protons of phenyl ring gave the AA'BB' systems as expected at 7.87 ppm (d, $J = 8.4$ Hz) and at 7.35 ppm (d, $J = 8.8$ Hz), respectively. Moreover, the proton H5 of the thiophene ring resonates as doublet of doublet ($J = 5.2, 1.2$ Hz) at 7.21 ppm, the H4 proton gave the doublet of doublet at 6.95 ppm ($J = 5.2, 3.6$ Hz), and the H3 proton gave the doublet at 7.05 ppm ($J = 3.6$ Hz), respectively. In addition, the protons of pyrazole ring gave the ABX system in the regions of 3.34 ppm (1H, HA, dd, $J_{AX} = 3.8$ Hz, dd, $J_{AB} = 17.6$ Hz), 3.75 ppm (1H, HB, dd, $J_{AB} = 17.6$ Hz, dd, $J_{BX} = 11.4$ Hz) and 5.96 ppm (1H(H5), HX, dd, $J_{AX} = 3.8$ Hz, dd, $J_{BX} = 11.4$ Hz), respectively. Furthermore, while the H8a proton of the isoxazole ring gave the doublet at 4.76 ppm ($J = 8.5$ Hz), the proton H3a gave the doublet at 3.02 ppm ($J = 8.8$ Hz). The H9 protons gave the AX system at 1.85 and 1.68 ppm ($J = 11.2$ Hz), respectively. Moreover, disappearance of double bond protons in the starting compounds in the ¹H-NMR spectrum and appearance of a signal at 81.5 ppm (C-O) in the ¹³C-NMR spectrum is evidence that the isoxazole ring is formed. All spectral data were in good agreement with the proposed structures.

4. Conclusion

In summary, a series of novel hybrid compounds ((3aS,4S,4aR,7aS,8S,8aS)-6-(4-(1-acetyl-5-(4-(aryl/heteroaryl))-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-3-methyl-4,4a,8,8a-tetrahydro-3aH-4,8-methanoisoxazolo [4,5-f] isoindole-5,7(6H,7aH)-dione derivatives) were synthesized by addition of acetaldoxime in the presence of NaOCl to starting compounds **1a-j** in moderate to good yields (54-75%). The structures of synthesized compounds **3a-j** were explained by spectral data (IR, ¹H-NMR and ¹³C-NMR) and Elemental analysis.

Acknowledgements

This article was produced from Msc Thesis of Fatih Ertürk. The authors are indebted to The Scientific and Technological Research Council of Turkey (TUBİTAK Project No: 111T990) for financial supports.

Supporting Information

Supporting information accompanies this paper on <http://www.acgpubs.org/journal/organic-communications>

ORCID Meliha Burcu Gürdere: [0000-0003-4285-5528](https://orcid.org/0000-0003-4285-5528)Fatih Ertürk: [0000-0003-3696-7558](https://orcid.org/0000-0003-3696-7558)Yakup Budak: [0000-0001-7108-5548](https://orcid.org/0000-0001-7108-5548)Mustafa Ceylan: [0000-0002-9184-4385](https://orcid.org/0000-0002-9184-4385)

References

- [1] Özbek, O.; Usta, N.C.; Gürdere, M.B.; Aslan, O.N.; Budak, Y.; Ceylan, M. Synthesis and antibacterial screening of novel 2-(4-(aryl) thiazol-2-yl)-3a,4,7,7a-tetrahydro-1H-4,7-ethanoisindole-1,3(2H)-dione derivatives. *Phosphor. Sulfur Silic. Relat. Elem.* **2017**, *192*, 1153-1157.
- [2] Gürdere, M.B.; Kamo, E.; Budak, Y.; Sahin Yağlıoğlu, A.; Ceylan, M. Synthesis and anticancer and cytotoxic effects of novel 1,4-phenylene-bis-N-thiocarbamoylpyrazole and 1,4-phenylene-bis-pyrazolylthiazole derivatives. *Turk. J. Chem.* **2017**, *41*, 179-189.
- [3] Yakalı, G.; Karabıyık, H.; Göksu, G.; Aygün M.; Öcal, N.; García-Granda, S. Supramolecular chirality-sensing DNA-mimicry of a norbornane derivative decorated with isoxazoline and methylpyrrolidine-2,5-dione ring. *J. Mol. Struct.* **2013**, *1041*, 164-174.
- [4] Gürdere, M.B.; Özbek, O.; Ceylan, M. Aluminum chloride-catalyzed C-alkylation of pyrrole and indole with chalcone and bis-chalcone derivatives. *Synt. Commun.* **2016**, *46*, 322-331.
- [5] Budak, Y.; Çakir A.D.; Özbek, O.; Gürdere, M.B.; Ceylan, M. Iodine-catalyzed addition of thiophenol to isoindolsubstitue chalcones. *BSEU J. Sci.* **2020**, *7*, 161-169.
- [6] Ye, N.; Zhu, Y-M.; Chen, H-J.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure-activity relationship studies of substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl cyanide analogues: Identification of potent exchange proteins directly activated by cAMP (EPAC) antagonists. *J. Med. Chem.* **2015**, *58*, 6033-6047.
- [7] Pankaj, V.; Khairnar, T.H.; Lung, Yi-J.; Lin, C.-Y.; Wu, S. R.; Koppolu, A.; Edukondalu, P.; Karanam, W. L. An intramolecular Wittig approach toward heteroarenes: Synthesis of pyrazoles, isoxazoles, and chromenone-oximes. *Org. Lett.* **2019**, *21(11)*, 4219-4223.
- [8] Daidone, G.; Raffa, D.; Maggio, B.; Plesica, F.; Cutili, V.M; Mangano, N.G.; Casuro, A. Synthesis and pharmacological activities of novel 3-(isoxazol-3-yl)-quinazolin-4(3H)-one derivatives. *Arch. Pharm.* **1999**, *332*, 50-54.
- [9] Bibi, H.; Nadeem, H.; Abbas, M. Synthesis and anti-nociceptive potential of isoxazole carboxamide derivatives. *BMC Chem.* **2019**, *29*, 13(1):6.
- [10] Çalışkan, B.; Sinoplu, E.; İbiş, K.; Güzelcan, A. E.; Atalay, Ç. R.; Banoglu, E. Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents *J. Enzyme Inhib. Med. Chem.* **2018**, *33(1)*, 1352-1361.
- [11] Pallepati, K.; Kancharlapalli, V. R.; Shaik, A. B. Synthesis, characterization and antitubercular evaluation of some new isoxazole appended 1-carboxamido-4,5-dihydro-1H-pyrazoles. *J. Res. Pharm.* **2019**, *23(2)*, 156-163.
- [12] Conti, P.; Amici, M.D.; Grazioso, G.; Roda, G.; Pinto, A.; Hansen, K.B.; Nielsen, B.; Madsen, U.; Bräuner-Osborne, H.; Egebjerg, J.; Vestri, V.; Pellegrini-Giampietro, D.E.; Sibille, P.; Acher, F.C.; Micheli, C.D. Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids. *J. Med. Chem.* **2005**, *48*, 6315-6325.
- [13] Srirastara, S.; Bajpai, L.K.; Batra, S.; Bhaduri, A.P.; Maikhuri, J.P.; Gupta, G.; Dhar, J.D. In search of new chemical entities with spermicidal and anti-HIV activities. *Bioorg. Med. Chem.* **1999**, *7*, 2607-2613.
- [14] Caramella, P.; Gruenanger, P. In: A. Padwa (Ed.), Wiley-Interscience, New York, 1984 vol 1.
- [15] Yeh, M. C. P.; Jou, C. F.; Yeh, W.T.; Chiu, D. Y.; Reddy, N. R. K. Intramolecular 1,3-dipolar cycloaddition of cyclo-1,3-diene-tethered nitrile oxides. *Tetrahedron* **2005**, *61*, 493-500.
- [16] Mishra, V. K.; Mishra, M.; Kashaw, V.; Kashaw, S. K. Synthesis of 1,3,5-trisubstituted pyrazolines as potential antimalarial and antimicrobial agents. *Bioorg. Med. Chem.* **2017**, *25(6)*, 1949-1962.
- [17] George, R. F.; Fouad, M. A.; Gomaa, I. E. O. Synthesis and cytotoxic activities of some pyrazoline derivatives bearing phenyl pyridazine core as new apoptosis inducers. *Eur. J. Med. Chem.* **2016**, *112*, 48-59.
- [18] Muneera, M. S.; Joseph, J. Design, synthesis, structural elucidation, pharmacological evaluation of metal complexes with pyrazoline derivatives. *J. Photoch. Photobio. B.* **2016**, *163*, 57-68.
- [19] Abid, M.; Azam, A. 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines: synthesis and *in vitro* antiamoebic activities. *Eur. J. Med. Chem.* **2005**, *40(9)*, 935-942.

- [20] Bandgar, B. P.; Adsul, L. K.; Chavan, H. V.; Jalde, S. S.; Shringare, S. N.; Shaikh, R.; Meshram, R. J.; Gacche, R. N.; Masand, V. Synthesis, biological evaluation, and docking studies of 3-(substituted)-aryl-5-(9-methyl-3-carbazole)-1H-2-pyrazolines as potent anti-inflammatory and antioxidant agents. *Bioorg. Med. Chem. Lett.* **2012**, *22(18)*, 5839-5844.
- [21] Bhosle, M. R.; Deshmukh, A. R.; Pal, S.; Srivastava, A. K.; Mane, R. A. Synthesis of new thiazolymethoxyphenyl pyrimidines and antihyperglycemic evaluation of the pyrimidines, analogues isoxazolines and pyrazolines. *Bioorg. Med. Chem. Lett.* **2015**, *25(11)*, 2442-2446.
- [22] Acharya, B. N.; Saraswat, D.; Tiwari, M.; Shrivastava, A. K.; Ghorpade, R.; Bapna, S.; Kaushik, M. P. Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines. *Eur. J. Med. Chem.* **2010**, *45(2)*, 430-438.
- [23] Gul, H. I.; Mete, E.; Taslimi, P.; Gulcin, I.; Supuran, C. T. Synthesis, carbonic anhydrase I and II inhibition studies of the 1,3,5-trisubstituted-pyrazolines. *J. Enzyme Inhib. Med. Chem.* **2017**, *32(1)*, 89-192.
- [24] Koçyiğit, Ü. M.; Budak, Y.; Gürdere, M. B.; Tekin, S.; Kul Köprülü, T.; Ertürk, F.; Özcan, K.; Gülçin, I.; Ceylan, M. Synthesis, characterization, anticancer, antimicrobial and carbonic anhydrase inhibition profiles of novel (3aR,4S,7R,7aS)-2-(4-((E)-3-(3-aryl)acryloyl) phenyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione derivatives. *Bioorg. Chem.* **2017**, *70*, 118-125.
- [25] Kocyiğit, Ü. M.; Budak, Y.; Gürdere, M. B.; Dürü, N.; Taslimi, P.; Gülçin, İ.; Ceylan, M. Synthesis and investigation of anticancer, antibacterial activities and carbonic anhydrase, acetylcholinesterase inhibition profiles of novel (3aR,4S,7R,7aS)- 2- [4- [1- acetyl- 5- (aryl/heteroaryl)- 4,5- dihydro- 1H-pyrazol-3-yl]phenyl]- 3a,4,7,7a - tetrahydro- 1H- 4,7- methanoisoindole- 1,3(2H)- diones. *Monatsh. Chem.* **2019**, *150*, 721-731.
- [26] Celik, C.; Kulu, I.; Ocal, N.; Kaufmann, D. E. Domino-Heck reactions of carba- and oxabicyclic, unsaturated dicarboximides: Synthesis of aryl-substituted, bridged perhydroisoindole derivatives. *Helv. Chim. Acta* **2009**, *92*, 1092-1101.
- [27] Peksel, A.; Celik, C.; Ocal, N.; Yanardag, R. Antioxidant and radical scavenging activities of some norcantharidin and bridged perhydroisoindole derivatives. *J. Serb. Chem. Soc.* **2013**, *78*, 15-25.

ACG
publications

© 2020 ACG Publications